Drug-Induced Movement Disorders
Drug-induced movement disorders (DIMDs) encompass a range of motor abnormalities caused by medications that affect dopaminergic, serotonergic, or other neurotransmitter systems. They are among the most common movement disorders encountered in clinical practice and are largely preventable. This article reviews the major categories: tardive syndromes, drug-induced parkinsonism, acute dystonic reactions, akathisia, neuroleptic malignant syndrome, serotonin syndrome, and drug-induced chorea/tremor.
Bottom Line
- Tardive dyskinesia: VMAT2 inhibitors (deutetrabenazine, valbenazine) are FDA-approved first-line treatments; prevention by minimizing dopamine blocker exposure is key
- Drug-induced parkinsonism: Second most common cause of parkinsonism; clinically indistinguishable from PD; typically resolves within weeks to months of stopping the offending agent, but may unmask prodromal PD
- Akathisia: Often misdiagnosed as anxiety or psychotic agitation; propranolol and benzodiazepines are first-line; dose reduction of the offending agent is essential
- NMS: Medical emergency (mortality 5–20%); immediate discontinuation of causative agent + supportive care + dantrolene/bromocriptine
- Serotonin syndrome: Clinical triad of altered mental status + autonomic instability + neuromuscular hyperactivity; cyproheptadine is the specific antidote
Tardive Syndromes
Epidemiology and Risk Factors
Tardive syndromes develop after prolonged exposure (≥3 months; ≥1 month in patients >60 years) to dopamine receptor-blocking agents (DRBAs). Prevalence: 20–30% of patients on long-term antipsychotic therapy.
| Risk Factor | Details |
|---|---|
| Age >55 years | Strongest risk factor; 5x higher incidence |
| Female sex | Higher risk, especially postmenopausal |
| African American descent | Higher risk (pharmacogenetic factors) |
| Duration of DRBA exposure | Cumulative dose-dependent |
| First-generation > second-generation antipsychotics | Typical antipsychotics have higher risk; clozapine has lowest risk |
| Mood disorders (vs. schizophrenia) | Patients with affective disorders at higher risk |
| Diabetes mellitus | Independent risk factor |
| Early EPS | Drug-induced parkinsonism or akathisia predicts higher TD risk |
Causative Agents
Any DRBA can cause tardive syndromes. Commonly implicated agents beyond antipsychotics:
- Antiemetics: Metoclopramide (most common non-psychiatric cause; FDA boxed warning for >12 weeks), prochlorperazine, promethazine
- Antidepressants: Amoxapine (D2 blocking properties)
- Atypical antipsychotics: All carry risk, though lower; quetiapine, olanzapine, risperidone; clozapine has the lowest risk and may actually treat TD
Clinical Subtypes
| Subtype | Description | Key Features |
|---|---|---|
| Tardive dyskinesia (TD) | Repetitive, stereotyped, purposeless movements | Classic orobuccolingual: lip smacking, tongue protrusion, chewing, lateral jaw movements; may also involve limbs and trunk |
| Tardive dystonia | Sustained or intermittent muscle contractions causing abnormal postures | More disabling than TD; retrocollis, opisthotonus, trunk extension; more common in younger males; often persists after DRBA withdrawal |
| Tardive akathisia | Persistent restlessness persisting >3 months after stable dose | Distinguished from acute akathisia by persistence; often coexists with TD |
| Tardive tremor | Postural/kinetic tremor, 3–5 Hz | Rare; may mimic essential tremor |
| Tardive tics / tourettism | Ticlike movements after DRBA exposure | Rare; may have premonitory urge |
| Tardive myoclonus | Brief jerking movements | Rare; may be generalized |
Assessment
The Abnormal Involuntary Movement Scale (AIMS) is the standard instrument: 12-item clinician-rated scale assessing facial/oral, extremity, and trunk movements, plus global severity and patient awareness. Total score range 0–40.
Treatment of Tardive Dyskinesia
TD Treatment Algorithm
- Prevention: Use lowest effective dose of DRBA for shortest duration; monitor with AIMS every 3–6 months (every 12 months for atypical antipsychotics)
- Reduce or discontinue DRBA if clinically feasible (risk of psychiatric decompensation; TD may initially worsen on withdrawal — “withdrawal dyskinesia”)
- Switch to lower-risk antipsychotic: Consider clozapine or quetiapine if antipsychotic is still needed
- VMAT2 inhibitor therapy (first-line):
- Valbenazine 40–80 mg daily (FDA approved for TD, 2017)
- Deutetrabenazine 12–48 mg/day in divided doses (FDA approved for TD, 2017)
- Both have Class I evidence; significant reduction in AIMS scores vs. placebo
- Adjunctive options (limited evidence): Tetrabenazine (off-label), clonazepam, ginkgo biloba extract (EGb-761), amantadine, vitamin B6
Drug-Induced Parkinsonism (DIP)
DIP is the second most common cause of parkinsonism after Parkinson disease, accounting for ~10–20% of parkinsonism cases. It can be clinically indistinguishable from PD.
| Feature | Details |
|---|---|
| Onset | Days to months after starting the offending agent; most within 1–3 months |
| Clinical features | Bilateral and symmetric (vs. asymmetric in PD); tremor may be absent or postural rather than resting; bradykinesia and rigidity prominent; may coexist with other DIMDs (akathisia, TD) |
| Causative agents | Antipsychotics (typical > atypical), antiemetics (metoclopramide, prochlorperazine), calcium channel blockers (flunarizine, cinnarizine), lithium, valproate, amiodarone, SSRIs |
| Resolution | Typically resolves within weeks to months of stopping the agent; may take up to 12 months. Persistence beyond 12 months suggests unmasking of underlying PD |
| DaTscan | Normal in pure DIP (intact presynaptic dopamine terminals); abnormal if underlying PD has been unmasked |
DIP vs. Parkinson Disease
Up to 15–20% of patients diagnosed with DIP are later diagnosed with PD. DIP may unmask prodromal PD by challenging an already compromised dopaminergic system. Any patient with persistent parkinsonism >6–12 months after drug withdrawal should be evaluated for underlying PD (consider DaTscan or clinical follow-up).
Acute Dystonic Reactions
- Onset: Usually within 24–96 hours of DRBA initiation (90% within first 5 days)
- Risk factors: Young age (children and young adults), male sex, high-potency antipsychotics, cocaine use
- Presentations: Oculogyric crisis (forced upward eye deviation), torticollis, trismus, tongue protrusion, opisthotonos, laryngospasm (potentially life-threatening)
- Treatment: IM or IV diphenhydramine (50 mg) or benztropine (1–2 mg); response typically within minutes. Continue oral anticholinergic for 48–72 hours to prevent recurrence
- Causative agents: Haloperidol, fluphenazine, metoclopramide, prochlorperazine; less common with atypical antipsychotics
Akathisia
A subjective sense of inner restlessness with an urge to move, typically manifesting as inability to sit still, rocking, pacing, or shifting weight. Often overlooked or misdiagnosed as anxiety, psychotic agitation, or RLS.
| Subtype | Timing | Features |
|---|---|---|
| Acute akathisia | Hours to days after starting/increasing DRBA | Most common; resolves with dose reduction or discontinuation |
| Tardive akathisia | ≥3 months on stable DRBA dose | Persists or worsens after DRBA withdrawal; often coexists with TD |
| Withdrawal akathisia | Within 6 weeks of DRBA discontinuation/dose reduction | Self-limited (usually 6 weeks) |
Assessment: Barnes Akathisia Rating Scale (BARS) — 4-item clinician-rated scale.
Treatment of Akathisia
- Step 1: Reduce dose of the offending agent or switch to a lower-risk agent (quetiapine, clozapine)
- Step 2: Propranolol 20–80 mg/day (most evidence; lipophilic beta-blocker preferred)
- Step 3: Benzodiazepines (lorazepam, clonazepam)
- Other options: Mirtazapine (5-HT2A antagonist properties), cyproheptadine, amantadine
- Anticholinergics: Less effective for akathisia than for other EPS; do NOT use as monotherapy
Neuroleptic Malignant Syndrome (NMS)
Medical Emergency
NMS is an idiosyncratic, life-threatening reaction to DRBAs, characterized by hyperthermia, severe rigidity, autonomic instability, and altered mental status. Mortality has declined from ~30% to 5–20% with earlier recognition and treatment.
| Feature | Details |
|---|---|
| Cardinal features | Hyperthermia (>38°C, often >40°C), severe “lead-pipe” rigidity, altered mental status (confusion → coma), autonomic instability (tachycardia, labile BP, diaphoresis) |
| Lab findings | Elevated CK (often >1,000 IU/L, can exceed 100,000), leukocytosis, elevated LDH, metabolic acidosis, myoglobinuria, acute kidney injury |
| Onset | Usually within 2 weeks of DRBA initiation or dose increase (90% within 10 days); can occur at any time |
| Risk factors | High-potency typical antipsychotics, rapid dose escalation, dehydration, agitation, IM administration, previous NMS episode (17–30% recurrence risk) |
| Causative agents | All antipsychotics; metoclopramide; also rapid withdrawal of dopaminergic agents in PD patients |
NMS Treatment
- Immediately discontinue the causative agent
- Aggressive supportive care: ICU admission, IV fluids, cooling measures, monitoring for renal failure, DVT, PE, DIC
- Dantrolene 1–2.5 mg/kg IV q6h (muscle relaxant; reduces rigidity and hyperthermia)
- Bromocriptine 2.5–10 mg PO/NG q8h (dopamine agonist; restores dopaminergic tone)
- Benzodiazepines for agitation and muscle rigidity
- ECT for refractory cases
Rechallenge: If antipsychotic is needed, wait ≥2 weeks, use a low-potency or atypical agent (clozapine, quetiapine), start at low dose, titrate slowly.
Serotonin Syndrome
A potentially life-threatening drug reaction caused by excessive serotonergic activity, most commonly from combining serotonergic agents.
| Domain | Features |
|---|---|
| Neuromuscular hyperactivity | Clonus (spontaneous, inducible, or ocular), hyperreflexia, myoclonus, tremor, rigidity (lower > upper extremity) |
| Autonomic instability | Hyperthermia, tachycardia, diaphoresis, diarrhea, mydriasis, labile BP |
| Altered mental status | Agitation, confusion, delirium |
Serotonin Syndrome vs. NMS
| Feature | Serotonin Syndrome | NMS |
|---|---|---|
| Onset | Rapid (hours) | Gradual (days) |
| Tone | Clonus, hyperreflexia (neuromuscular excitation) | Lead-pipe rigidity (bradykinetic) |
| Pupils | Mydriasis (dilated) | Normal |
| Bowel sounds | Hyperactive | Normal or decreased |
| CK | Mildly elevated (usually <1,000) | Markedly elevated (often >1,000–100,000) |
| Causative drugs | Serotonergic agents (SSRIs, SNRIs, MAOIs, tramadol, linezolid, triptans) | Dopamine receptor blockers |
| Treatment | Cyproheptadine (5-HT2A antagonist) + benzodiazepines | Dantrolene + bromocriptine |
| Resolution | 24–72 hours (rapid after drug removal) | Days to weeks |
Drug-Induced Chorea
Multiple drug classes can induce choreiform movements:
| Drug Class | Examples |
|---|---|
| Antiparkinsonism | Levodopa (peak-dose dyskinesia in PD), dopamine agonists, anticholinergics |
| Dopamine antagonists | Tardive syndromes (see above) |
| Antiseizure medications | Phenytoin, carbamazepine, lamotrigine, gabapentin, valproic acid |
| Antidepressants | TCAs, SSRIs |
| Stimulants | Cocaine, amphetamines |
| Oral contraceptives | Chorea gravidarum; recurrence of Sydenham chorea |
| Others | Baclofen, calcium channel blockers, digoxin, fluoroquinolones, steroids, methadone |
Drug-Induced Tremor
| Tremor Type | Common Causative Agents |
|---|---|
| Enhanced physiologic tremor | Sympathomimetics (albuterol, theophylline), caffeine, lithium, valproate, thyroid hormones, SSRIs |
| Parkinsonian tremor | Antipsychotics, metoclopramide, valproate (may cause both action and resting tremor) |
| Cerebellar/intention tremor | Lithium (toxicity), phenytoin, carbamazepine, 5-FU, cytarabine |
Management: Dose reduction or discontinuation of the causative agent is the primary intervention. For essential lithium or valproate therapy, propranolol may reduce tremor amplitude. Dose fractionation or switching to extended-release formulations can also help.
References
- Continuum (Minneap Minn). August 2025; 31(4 Movement Disorders). Huntington Disease and Chorea (pp 1066–1087).
- Caroff SN, Campbell EC. Drug-induced extrapyramidal syndromes. Psychiatr Clin North Am. 2016;39(3):391–411.
- Ricciardi L, Pringsheim T, Barnes TRE, et al. Treatment recommendations for tardive dyskinesia. Can J Psychiatry. 2019;64(6):388–399.
- Ware MR, Feller DB, Hall KL. Neuroleptic malignant syndrome: diagnosis and management. Prim Care Companion CNS Disord. 2018;20(1):17r02185.
- Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112–1120.